Why McKesson (MCK) Dipped More Than Broader Market Today

McKesson (MCK) shares closed down 2.99% at $693.54, significantly underperforming the broader market's modest declines. Despite this daily underperformance, the stock has gained 1.34% over the past month, outpacing its Medical sector peers. Looking ahead, analysts project strong growth for McKesson, with Q1 2025 earnings expected to rise 4.44% year-over-year to $8.23 per share and revenue up 21.18% to $96.08 billion. The company currently holds a Zacks Rank #2 (Buy), supported by a 0.08% increase in consensus EPS estimates over the last month, and trades at a premium Forward P/E but a favorable PEG ratio within its highly-ranked Medical - Dental Supplies industry.

Analysis

Despite a significant single-day decline of 2.99%, McKesson Corporation (MCK) exhibits strong underlying fundamentals and a positive forward outlook. Over the past month, the stock has gained 1.34%, outperforming the broader Medical sector's 0.88% loss, though it has lagged the S&P 500. Analyst consensus points to robust growth, with upcoming quarterly revenue projected to increase 21.18% year-over-year to $96.08 billion and full-year earnings per share expected to grow by 12.74%. This positive sentiment is reinforced by a recent upward revision in the Zacks Consensus EPS estimate and a Zacks Rank of #2 (Buy). While the stock trades at a premium Forward P/E of 19.19 compared to its industry average of 17.82, its PEG ratio of 1.45 is more favorable than the industry average of 1.76, suggesting its growth prospects may justify the higher valuation. Furthermore, MCK operates within the Medical - Dental Supplies industry, which ranks in the top 12% of over 250 industries, providing a strong sector backdrop.

Key Decisions for Investors

• The recent 2.99% price drop could be viewed as a tactical entry point for investors aligned with the bullish consensus, given the strong forward-looking growth projections.
• Investors should closely monitor the upcoming August 6, 2025 earnings report, as delivering on the high expectations for revenue (+21.18% YoY) will be critical to sustaining momentum.
• While the PEG ratio of 1.45 is attractive, the premium Forward P/E implies that strong growth is already priced in, leaving little room for execution missteps.
• Consider the combination of a #2 (Buy) rating and the stock's position in a top-quartile industry as a strong quantitative justification for a continued overweight or new long position, pending risk tolerance.